Roche announces CHMP recommendation for EU approval of Venclyxto plus MabThera for people with previously treated chronic lymphocytic leukaemia
Roche announced today that the EU Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Venclyxto ® (venetoclax) in combination with MabThera® (rituximab) for the treatment of people with chronic lymphocytic leukaemia (CLL) who have received at least one prior therapy. (Source: Roche Investor Update)
Source: Roche Investor Update - September 21, 2018 Category: Pharmaceuticals Source Type: news
Critically Elevated Potassium in Chronic Lymphocytic Leukemia Critically Elevated Potassium in Chronic Lymphocytic Leukemia
A misdiagnosis as to the cause of hyperkalemia in this patient led to unnecessary dialysis, demonstrating the need to be alert to potentially false potassium results in patients with elevated WBC counts.Laboratory Medicine (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 19, 2018 Category: Consumer Health News Tags: Pathology & Lab Medicine Journal Article Source Type: news
Stress linked to more advanced disease in some leukemia patients
(Ohio State University) Patients with chronic lymphocytic leukemia (CLL) who feel more stress also have more cancer cells in their blood and elevated levels of three other markers of more advanced disease. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - September 11, 2018 Category: Cancer & Oncology Source Type: news
Melanoma Linked with CLL, Wilmot Recommends Close Monitoring
While studying a large group of individuals with chronic lymphocytic leukemia (CLL), a Wilmot Cancer Institute scientific team made an important discovery — these patients had a sizable 600 percent higher risk of melanoma, the most dangerous form of skin cancer. (Source: University of Rochester Medical Center Press Releases)
Source: University of Rochester Medical Center Press Releases - August 14, 2018 Category: Universities & Medical Training Authors: University of Rochester Medical Center Source Type: news
Medical News Today: What is the outlook for chronic lymphocytic leukemia?
Chronic lymphocytic leukemia (CLL) is a type of cancer that affects the blood and bone marrow. Although doctors can very rarely cure CLL, survival rates for this cancer are typically good. A person ’s life expectancy for CLL depends on how far the cancer has progressed and when they receive treatment. Learn more here. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - August 13, 2018 Category: Consumer Health News Tags: Leukemia Source Type: news
Melanoma linked with CLL, close monitoring recommended
(University of Rochester Medical Center) While studying a large group of individuals with chronic lymphocytic leukemia (CLL), a Wilmot Cancer Institute scientific team made an important discovery -- these patients had a sizable 600 percent higher risk of melanoma, the most dangerous form of skin cancer. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - August 9, 2018 Category: International Medicine & Public Health Source Type: news
Mutations in Half of Patients With CLL Who Relapse on Ibrutinib Mutations in Half of Patients With CLL Who Relapse on Ibrutinib
Acquired mutations were present in 50% of patients with chronic lymphocytic leukemia (CLL) who relapsed after treatment with ibrutinib (Imbruvica).Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 27, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
Survival Longer With Obinutuzumab Compared to Rituximab in CLL Survival Longer With Obinutuzumab Compared to Rituximab in CLL
New longer-term results with overall survival data confirm the superiority of the newer agent over the earlier-generation anti-CD20 drug rituximab for previously untreated chronic lymphocytic leukemia (CLL).Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - June 20, 2018 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
AbbVie Announces New Undetectable Minimal Residual Disease Data from Phase 3 Relapsed/Refractory Chronic Lymphocytic Leukemia MURANO Trial of Venetoclax in Combination with Rituximab at 23rd European Hematology Association Annual Congress
83 percent (n=100) of 121 patients who achieved undetectable minimal residual disease (uMRD) at the end of combination therapy with VenR (n=194), maintained uMRD and were progression-free at 13.8 months of follow-up[1]
uMRD response rates were consisten... Biopharmaceuticals, Oncology AbbVie, MURANO trial, venetoclax, chronic lymphocytic leukemia (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - June 15, 2018 Category: Pharmaceuticals Source Type: news
New long-term data confirm Roche ’s Gazyva/Gazyvaro extends the lives of people with chronic lymphocytic leukaemia compared to MabThera/Rituxan
Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced data from the final analysis of the CLL11 study evaluating Gazyva®/Gazyvaro® (obinutuzumab)-based treatment in previously untreated chronic lymphocytic leukaemia (CLL) which will be presented during the Presidential Symposium at the 23rd European Hematology Association (EHA) Annual Congress, 14 - 17 June, in Stockholm. (Source: World Pharma News)
Source: World Pharma News - June 15, 2018 Category: Pharmaceuticals Tags: Featured Roche Business and Industry Source Type: news
New long-term data confirm Roche ’s Gazyva/Gazyvaro extends the lives of people with chronic lymphocytic leukaemia compared to MabThera/Rituxan
Roche today announced data from the final analysis of the CLL11 study evaluating Gazyva ®/Gazyvaro® (obinutuzumab)-based treatment in previously untreated chronic lymphocytic leukaemia (CLL) which will be presented during the Presidential Symposium at the 23rd European Hematology Association (EHA) Annual Congress, 14 - 17 June, in Stockholm. (Source: Roche Media News)
Source: Roche Media News - June 15, 2018 Category: Pharmaceuticals Source Type: news
New long-term data confirm Roche ’s Gazyva/Gazyvaro extends the lives of people with chronic lymphocytic leukaemia compared to MabThera/Rituxan
Roche today announced data from the final analysis of the CLL11 study evaluating Gazyva ®/Gazyvaro® (obinutuzumab)-based treatment in previously untreated chronic lymphocytic leukaemia (CLL) which will be presented during the Presidential Symposium at the 23rd European Hematology Association (EHA) Annual Congress, 14 - 17 June, in Stockholm. (Source: Roche Investor Update)
Source: Roche Investor Update - June 15, 2018 Category: Pharmaceuticals Source Type: news
Roche announces FDA approval for Venclexta plus Rituxan for people with previously treated chronic lymphocytic leukaemia
Roche, announced today that the United States Food and Drug Administration (FDA) has approved Venclexta ® (venetoclax) in combination with Rituxan® (rituximab) for the treatment of people with chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL), with or without 17p deletion, who have received at least one prior therapy. (Source: Roche Media News)
Source: Roche Media News - June 11, 2018 Category: Pharmaceuticals Source Type: news
Roche announces FDA approval for Venclexta plus Rituxan for people with previously treated chronic lymphocytic leukaemia
Roche, announced today that the United States Food and Drug Administration (FDA) has approved Venclexta ® (venetoclax) in combination with Rituxan® (rituximab) for the treatment of people with chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL), with or without 17p deletion, who have received at least one prior therapy. (Source: Roche Investor Update)
Source: Roche Investor Update - June 11, 2018 Category: Pharmaceuticals Source Type: news
The cancer revolution: How you can benefit from a new test which could mean no more chemo
Mike Brandon, 34, from Bristol was diagnosed with chronic lymphocytic leukaemia which is deemed untreatable in the UK but he was able to undergo specialised life-saving therapy in the US. (Source: the Mail online | Health)
Source: the Mail online | Health - June 10, 2018 Category: Consumer Health News Source Type: news
